API | ravidasvir

ravidasvir Report issue

Small molecule Experimental

AACT ChEMBL PubChem

Active Ingredient History

NOW

Ravidasvir (PPI-668) is an investigational NS5A inhibitor in clinical trials for chronic hepatitis C genotype 4. ^Wikipedia

Chemistry

SMILES: COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c2ncc([nH]2)c3ccc4cc(ccc4c3)c5ccc6nc([nH]c6c5)[C@@H]7CCCN7C(=O)[C@@H](NC(=O)OC)C(C)C
InChIKey: LCHMHYPWGWYXEL-ZYADHFCISA-N
Mol. Mass: 762.91
ALogP: 6.86 Partition coefficient
ChEMBL Molecules:

ravidasvir

ravidasvir hydrochloride

More Chemistry

Pharmacology

Mechanism of Action:
- Genome polyprotein (Hepatitis C virus genotype 1b (strain HC-J4) (HCV)) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

bi-238630 | bi-238630-cl2 | c5 | ppi-668 | ppi-668 free base | ravidasvir | ravidasvir hydrochloride

Organizations (9)

Research & Development (9)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (4)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (4)

Drugs, Generic (Phase 1)

Healthy Volunteers (Phase 1)

Hepatitis C (Phase 2/Phase 3)

Hepatitis C, Chronic (Phase 2/Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 14
# of Trial Organizations: 9

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue